Characteristics
Renal transplant recipients(n=9)
Hepatic transplant recipients(n=5)
Transplant Group (All recipients; n=14) Control Group (n=56)
P-value*
Age, years 57.9±3.7 61.0±7.9 59.0±5.5 59.1±5.3 0.797
Male, n (%) 7(77.8) 4(80.0) 11(78.6) 44(78.6) 1.000
BMI, Kg/m2 26.8±5.0 25.2±1.3 26.2±4.1 26.3±1.9 0.702
AF duration, months 44.9±38.9 52.6±59.3 47.6±45.1 49.4±54.4 0.819
Type of AF, n (%) 1.000
Persistent AF 2(22.2) 1(20.0) 3(21.4) 12(21.4)
Paroxysmal AF 7(77.8) 4(80.0) 11(78.6) 44(78.6)
Congestive heart failure, n (%) 1(11.1) 0(0.0) 1(7.1) 3(5.4) 1.000
Hypertension, n (%) 7(77.8) 4(80.0) 11(78.6) 34(60.7) 0.350
Diabetes mellitus, n (%) 2(22.2) 1(20.0) 3(21.4) 15(26.8) 1.000
Stroke/TIA, n (%) 1(11.1) 1(20.0) 2(14.3) 4(7.1) 0.592
Coronary heart disease, n (%) 4(44.4) 0(0.0) 4(28.6) 6(10.7) 0.104
Laboratory characteristics
Hemoglobin, g/L 144.1±16.9 157.0±23.5 148.7±19.7 151.3±14.5 0.649
Platelet, 109/L 215.3±78.9 169.2±47.4 198.8±71.0 209.7±49.0 0.209
ALT, IU/L 18.8±10.3 24.6±10.5 20.9±10.4 22.8±10.8 0.814
AST, IU/L 21.3±5.2 24.8±5.5 22.6±5.4 21.8±5.1 0.417
Total bilirubin, μmol/L 16.6±3.3 19.0±10.0 17.5±6.2 15.8±6.2 0.325
Direct bilirubin, μmol/L 4.1±1.0 3.6±1.4 3.9±1.1 3.4±1.3 0.144
Creatinine, μmol/L 89.4±27.7 86.7±11.8 88.4±22.8 74.6±14.7 0.017
eGFR, ml/min/1.73m2 80.4±15.6 80.3±11.9 80.3±13.9 91.9±12.6 0.007
Echocardiographic parameters
LAD, mm 39.1±6.3 40.4±4.6 39.6±5.6 39.5±3.1 0.929
LVEDD, mm 49.9±6.1 45.2±3.0 48.2±5.6 48.7±3.7 0.802
LVEF, % 61.2±6.8 62.4±2.8 61.6±5.6 63.4±4.1 0.430
EHRA stratification, n (%) 0.812
EHRA II 1(11.1) 1(20.0) 2(14.3) 10(17.9)
EHRA III 7(77.8) 4(80.0) 11(78.6) 44(78.6)
EHRA IV 1(11.1) 0(0.0) 1(7.1) 2(3.6)
CHA2DS2-VASC score 2.1±0.8 2.0±1.2 2.1±0.9 1.2±1.1 0.002
HAS-BLED score 1.9±0.3 2.4±0.9 2.1±0.6 0.9±0.7 <0.001
OAC
Warfarin, n (%) 4(44.4) 1(20.0) 5(35.7) 9(16.1) 0.135
NOAC, n (%) 5(55.6) 4(80.0) 9(64.3) 47(83.9) 0.135